BG Investment Services LLC Acquires 6,371 Shares of AbbVie Inc. $ABBV

Key Points

• BG Investment Services acquired 6,371 AbbVie shares worth approximately $1.67 million in the third quarter. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie received FDA approval for a more convenient subcutaneous induction regimen of SKYRIZI for Crohn’s disease, supporting the company’s post-Humira growth strategy. The company’s dividend also remains a key investor attraction.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $279.86 price target, though upcoming earnings face scrutiny given AbbVie’s premium valuation and shares near their 52-week high.

BG Investment Services LLC bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,371 shares of the company's stock, valued at approximately $1,667,000.

Other large investors have also recently made changes to their positions in the company. State Street Corp lifted its position in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new position in AbbVie during the 2nd quarter worth approximately $2,905,952,000. Deutsche Bank AG increased its position in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Finally, Amundi increased its position in AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company's stock worth $2,326,728,000 after purchasing an additional 247,689 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Bank of America reissued a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Scotiabank boosted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Piper Sandler increased their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Finally, The Goldman Sachs Group upped their target price on AbbVie from $258.00 to $294.00 and gave the company a "neutral" rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $279.86.

AbbVie Stock Up 0.0%

Shares of NYSE:ABBV opened at $285.66 on Monday. The company has a market cap of $504.70 billion, a P/E ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24. The business has a fifty day simple moving average of $266.33 and a 200-day simple moving average of $242.01. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.